The FY2025 (Dec) proxy of AbbVie names 9 peer companies for pay. Among AbbVie and these peers, CEO pay was 3rd highest of 8 and total shareholder return was 2nd highest of 8.
3rd highest of 8in AbbVie and its pay peers, FY2025 (Dec) by CEO pay:
$20.8M$36.7M
2nd highest of 8in AbbVie and its pay peers, FY2025 (Dec) by total shareholder return:
$86$671
Pay peer group, FY2025 (Dec) proxy
| Eli Lilly & Co | ||
| Johnson & Johnson | ||
| Gilead Sciences | ||
| Pfizer | ||
| Amgen | ||
| Bristol Myers Squibb | ||
| Merck & Co. | ||
| GlaxoSmithKline plc | Not disclosed | Not disclosed |
| Novartis AG | Not disclosed | Not disclosed |
9 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.